Top

Published in:

Open Access 01-10-2009 | Original Article

Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy

Authors: Richard M. de Jong, MD, PhD, Rene A. Tio, MD, PhD, Pim van der Harst, MD, PhD, Adriaan A. Voors, MD, PhD, Paul M. Koning, BSc, Clark J. A. M. Zeebregts, MD, PhD, Dirk J. van Veldhuisen, MD, PhD, Rudi A. J. O. Dierckx, MD, PhD, Riemer H. J. A. Slart, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 5/2009

Abstract

Background

Although patients with idiopathic dilated cardiomyopathy (DCM) have no coronary artery disease, regional impairment of myocardial perfusion combined with preserved metabolism has been found using positron emission tomography (PET). Our aim was to assess the prognostic relevance of PET-mismatch between stress myocardial perfusion and glucose uptake on clinical outcome in DCM.

Methods

In 24 patients with DCM who underwent both myocardial perfusion and metabolism PET scanning, “mismatch” was assessed and the association with clinical outcome (hospitalization, mortality, and heart transplantation) was investigated.

Results

Mismatch was found in 16 patients (66.7%). Univariate analysis showed that the presence of mismatch was associated with adverse outcome (P = 0.03). After adjustment for sex and age, the association remained significant with an adjusted relative risk of 10.4 (95% CI 1.1-103; P = 0.04) for death, heart transplant, or hospitalization. Univariate analysis also showed that a higher extent of mismatch was significantly associated with adverse outcome (P = 0.02). After adjusting for sex and age, the association remained significant with an adjusted relative risk of 6.5 [95% CI 1.2-36; P = 0.03] for death, heart transplantation, or hospitalization.

Conclusion

PET stress perfusion-metabolism mismatch, indicative for ischemia, is frequently found in DCM patients and related to a poorer outcome.

Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990;81:772-9.PubMed

Juilliere Y, Marie PY, Danchin N, et al. Radionuclide assessment of regional differences in left ventricular wall motion and myocardial perfusion in idiopathic dilated cardiomyopathy. Eur Heart J 1993;14:1163-9.PubMed

Blanksma PK, Willemsen AT, Meeder JG, et al. Quantitative myocardial mapping of perfusion and metabolism using parametric polar map displays in cardiac PET. J Nucl Med 1995;36:153-8.PubMed

Abbott BG, Liu YH, Arrighi JA. [18F]Fluorodeoxyglucose as a memory marker of transient myocardial ischaemia. Nucl Med Commun 2007;28:89-94.PubMedCrossRef

Dou KF, Yang MF, Yang YJ, Jain D, He ZX. Myocardial 18F-FDG uptake after exercise-induced myocardial ischemia in patients with coronary artery disease. J Nucl Med 2008;49:1986-91.PubMedCrossRef

van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000;35:19-28.PubMedCrossRef

Erdogan D, Gullu H, Caliskan M, et al. Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Heart 2007;93:319-24.PubMedCrossRef

Neglia D, De Maria R, Masi S, et al. Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy. Heart 2007;93:808-13.PubMedCrossRef

De Boer RA, Pinto YM, van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: The role of microvascular growth and abnormalities. Microcirculation 2003;10:113-26.PubMedCrossRef

10.

Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995;92:3436-44.PubMed

11.

Senior R, Kaul S, Raval U, Lahiri A. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99 m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 2002;9:454-62.PubMedCrossRef

12.

Schelbert HR, Phelps ME, Huang SC, et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation 1981;63:1259-72.PubMed

13.

Choi Y, Hawkins RA, Huang SC, et al. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18F]fluoro-2-deoxy-d-glucose studies. J Nucl Med 1991;32:733-8.PubMed

14.

Sharpe N. Cardiac remodeling in coronary artery disease. Am J Cardiol 2004;93:17B-20B.PubMedCrossRef

15.

Unverferth DV, Magorien RD, Lewis RP, Leier CV. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 1983;105:176-9.PubMedCrossRef

16.

Abraham D, Hofbauer R, Schafer R, et al. Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res 2000;87:644-7.PubMed

17.

De Boer RA, Henning RH, Tio RA, et al. Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy. Heart 2002;88:412-4.PubMedCrossRef

18.

Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80:15L-25L.PubMedCrossRef

19.

Mosseri M, Schaper J, Admon D, et al. Coronary capillaries in patients with congestive cardiomyopathy or angina pectoris with patent main coronary arteries. Ultrastructural morphometry of endomyocardial biopsy samples. Circulation 1991;84:203-10.PubMed

20.

Figulla HR, Vetterlein F, Glaubitz M, Kreuzer H. Inhomogenous capillary flow and its prevention by verapamil and hydralazine in the cardiomyopathic Syrian hamster. Circulation 1987;76:208-16.PubMed

21.

Inoue A, Fujimoto S, Yamashina S, Yamazaki J. Prediction of cardiac events in patients with dilated cardiomyopathy using 123I-BMIPP and 201Tl myocardial scintigraphy. Ann Nucl Med 2007;21:399-404.PubMedCrossRef

22.

Isobe S, Ando A, Nanasato M, et al. Combined study with FDG PET and Tl SPECT in patients with idiopathic dilated cardiomyopathy. Nucl Med Commun 2003;24:1071-80.PubMedCrossRef

23.

de Jong RM, Cornel JH, Crijns HJ, van Veldhuisen DJ. Abnormal contractile responses during dobutamine stress echocardiography in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail 2001;3:429-36.PubMedCrossRef

24.

Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72:V123-35.PubMed

25.

Bax JJ, Cornel JH, Visser FC, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol 1997;30:377-83.PubMedCrossRef

26.

Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 2002;8:S465-71.PubMedCrossRef

27.

van Veldhuisen DJ, van den Heuvel AF, Blanksma PK, Crijns HJ. Ischemia and left ventricular dysfunction: A reciprocal relation? J Cardiovasc Pharmacol 1998;32:S46-51.PubMed

28.

Canty JM Jr, Suzuki G, Banas MD, Verheyen F, Borgers M, Fallavollita JA. Hibernating myocardium: Chronically adapted to ischemia but vulnerable to sudden death. Circ Res 2004;94:1142-9.PubMedCrossRef

29.

Westenbrink BD, Oeseburg H, Kleijn L, et al. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 2008;22:265-74.PubMedCrossRef

30.

Belonje AM, Voors AA, van Gilst WH, van Veldhuisen DJ. Erythropoietin in chronic heart failure. Congest Heart Fail 2007;13:289-92.PubMedCrossRef

Title: Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy
Authors: Richard M. de Jong, MD, PhD
Rene A. Tio, MD, PhD
Pim van der Harst, MD, PhD
Adriaan A. Voors, MD, PhD
Paul M. Koning, BSc
Clark J. A. M. Zeebregts, MD, PhD
Dirk J. van Veldhuisen, MD, PhD
Rudi A. J. O. Dierckx, MD, PhD
Riemer H. J. A. Slart, MD, PhD
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Journal of Nuclear Cardiology / Issue 5/2009
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-009-9130-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2009

Role of Tc-99m sestamibi myocardial perfusion imaging in identifying multiple myeloma

Developing a new PET myocardial perfusion tracer

Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis

Capping it off

Clinical effectiveness of coronary computed tomographic angiography in the triage of patients to cardiac catheterization and revascularization after inconclusive stress testing: results of a 2-year prospective trial

Focal breast uptake of 99m-Tc sestamibi in a hematoma